ENLV Stock Analysis: Buy, Sell, or Hold?
ENLV - Enlivex Therapeutics Ltd. Ordinary Shares
$7.12
6.64 (1381.79%)
▲
5d:
+1214.62%
30d:
+896.92%
90d:
+663.05%
WAIT
LOW Confidence
Analysis Updated: Jul 9, 2026 12:00 AM ET
Earnings: May 29, 2026
0d
Get Alerted When ENLV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ENLV is 836.8% above its trading range ($0.76). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ENLV is 836.8% above its trading range ($0.76). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ENLV is currently trading at $7.12, which is considered oversold relative to its 30-day fair value range of $0.55 to $0.76.
Technical Outlook: Technically, ENLV is in a strong downtrend. The price is approaching resistance at $0.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 1381.8% recently.
Market Sentiment: ENLV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.00 (+4062.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENLV is in a strong downtrend. The price is approaching resistance at $0.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 1381.8% recently.
Market Sentiment: ENLV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.00 (+4062.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.55 -
$0.76
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+1381.8%)
- BULLISH: Trading 4062.3% below Wall St target ($20.00)
- WARNING: Recommendation downgraded due to 836.8% overvaluation
Trading Range Analysis
30-Day Trading Range
$0.55 -
$0.76
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.68
Resistance Level
$0.90
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.34
Wall Street Target
$20.00
(+4062.3%)
Share & Embed Analysis
Last updated: July 09, 2026 1:59 PM ET
Data refreshes hourly during market hours. Next update: 2:59 PM
Data refreshes hourly during market hours. Next update: 2:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENLV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 62 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
